Influential cancer group to add drug-cost data to its treatment advice

When a U.S. cancer patient is prescribed drugs by their doctors now, the financial consequences play out over the course of treatment. But amid a growing national debate over drug prices, an influential coalition of cancer treatment centers, the National Comprehensive Cancer Network, will provide patients with info on the relative costs of different treatments, so they and their doctors can make more informed decisions. More from FiercePharma

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.